Bioanalytical challenges in development of biosimilars
drug, bound drug, or free drug to determine what fraction of the dose is bioavailable. The PK assay method must be able to permit demonstration of bioequivalence of the biosimilar
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
drug, bound drug, or free drug to determine what fraction of the dose is bioavailable. The PK assay method must be able to permit demonstration of bioequivalence of the biosimilar
This presentation addresses the basic requirement of having process controls based on
According to a recent FDA guidance, a biosimilar is a biological product
The aim of this presentation is to introduce the principles and practice
Amal Ali Elkordy is a Senior Lecturer in Pharmaceutics in the Department
David Goodall is CSO and founder of Paraytec Limited, based in York
Preventing relapse from early stage cancer is a major unsolved problem in
When an innovator biological product is going off patient, biopharmaceutical and/or
Advanced analytical technologies have provided approaches in analyzing the bioactivities of single
substances between intra- and extracellular mediums which is controlled by cell metabolism. Therefore, the bioavailability and bioequivalence of factors will be determined by their ability to stabilize or increase these
The harvesting and storing of alfalfa is a routine practice in the
Ageing population, rising health care expectations and now, new-marketed biologic drugs
Gastric peptide ghrelin and GHS-R may be promising therapeutic targets for
The patent term of some of the most important biopharmaceutic blockbusters is
Two years have passed since Congress, as part of the 2010 Health
Recent advances in mammalian cell culture technology has resulted in significant increases
Plant can be used as an alternative expression system for production of
with β-CD (β-Cyclodextrin) and enhanced solubility up to 10~fold and oral bioavailability up to 2~fold. The plasma half-life was improved by customizing long circulating stealth
During last decade, enormous efforts have been made to harmonize international validation
While biosimilars have triggered a major regulatory debate in regulated markets, emerging
Biosimilar pharmaceuticals are complex biological molecules that have similar physicochemical properties to
HPV-16 is reported as the cause of cervical and other related
An effective tuberculosis (TB) vaccine could have a significant impact on the
Monoclonal antibodies (Mabs) are now the second largest category of biopharmaceutical products
Hatim Motiwala is a postgraduate in Microbiology and at completion stage of
For authors and organisers
Find the right journal for your paper and submit your manuscript.